These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 10438416)
21. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. Brache V; Merkatz R; Kumar N; Jesam C; Sussman H; Hoskin E; Roberts K; Alami M; Taylor D; Jorge A; Croxatto H; Lorange E; Mishell DR; Sitruk-Ware R Contraception; 2015 Oct; 92(4):289-97. PubMed ID: 26032952 [TBL] [Abstract][Full Text] [Related]
22. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435. Laurikka-Routti M; Haukkamaa M; Lähteenmäki P Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309 [TBL] [Abstract][Full Text] [Related]
23. Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435. Lähteenmäki PL; Diaz S; Miranda P; Croxatto H; Lähteenmäki P Contraception; 1990 Nov; 42(5):555-62. PubMed ID: 2272183 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148 [TBL] [Abstract][Full Text] [Related]
26. Simultaneous assay of segesterone acetate (Nestorone®), estradiol, progesterone, and estrone in human serum by LC-MS/MS. Erikson DW; Blue SW; Fecteau KM; Edelman AB; Jensen JT; Blithe DL Contraception; 2020 Nov; 102(5):361-367. PubMed ID: 32828731 [TBL] [Abstract][Full Text] [Related]
27. Association of Etonogestrel-Releasing Contraceptive Implant with Reduced Weight Gain in an Exclusively Breastfed Infant: Report and Literature Review. Stuebe AM; Bryant AG; Lewis R; Muddana A Breastfeed Med; 2016 May; 11(4):203-6. PubMed ID: 27032034 [TBL] [Abstract][Full Text] [Related]
28. Endometrial histology, microvascular density and caliber, and matrix metalloproteinase-3 in users of the Nestorone-releasing contraceptive implant with and without endometrial breakthrough bleeding. Oliveira-Ribeiro M; Petta CA; De Angelo Andrade LA; Hidalgo MM; Pellogia A; Bahamondes L Contraception; 2006 Jun; 73(6):634-40. PubMed ID: 16730498 [TBL] [Abstract][Full Text] [Related]
29. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol. Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374 [TBL] [Abstract][Full Text] [Related]
30. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception. Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294 [TBL] [Abstract][Full Text] [Related]
32. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Truitt ST; Fraser AB; Grimes DA; Gallo MF; Schulz KF Cochrane Database Syst Rev; 2003; (2):CD003988. PubMed ID: 12804497 [TBL] [Abstract][Full Text] [Related]
33. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Yuen F; Wu S; Thirumalai A; Swerdloff RS; Page ST; Liu PY; Dart C; Wu H; Blithe DL; Sitruk-Ware R; Long J; Bai F; Hull L; Bremner WJ; Anawalt BD; Wang C Andrology; 2019 Mar; 7(2):235-243. PubMed ID: 30556332 [TBL] [Abstract][Full Text] [Related]
34. [Family planning during breast feeding]. Peralta O; Díaz S; Croxatto H Rev Chil Pediatr; 1989; 60 Suppl 2():19-23. PubMed ID: 2519785 [TBL] [Abstract][Full Text] [Related]
35. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Simmons KB; Kumar N; Plagianos M; Roberts K; Hoskin E; Han L; Alami M; Creasy G; Variano B; Merkatz R Contraception; 2018 Mar; 97(3):270-276. PubMed ID: 29097225 [TBL] [Abstract][Full Text] [Related]
36. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Zitzmann M; Rohayem J; Raidt J; Kliesch S; Kumar N; Sitruk-Ware R; Nieschlag E Andrology; 2017 May; 5(3):516-526. PubMed ID: 28189123 [TBL] [Abstract][Full Text] [Related]
38. Gonadotropin-releasing hormone antagonist for postpartum contraception: outcome for the mother and male offspring in the marmoset. Fraser HM; Recio R; Conn PM; Lunn SF J Clin Endocrinol Metab; 1994 Jan; 78(1):121-5. PubMed ID: 8288695 [TBL] [Abstract][Full Text] [Related]
39. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Sivin I; Mishell DR; Alvarez F; Brache V; Elomaa K; Lähteenmäki P; Massai R; Miranda P; Croxatto H; Dean C; Small M; Nash H; Jackanicz TM Contraception; 2005 Feb; 71(2):122-9. PubMed ID: 15707562 [TBL] [Abstract][Full Text] [Related]
40. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Ylänen K; Laatikainen T; Lähteenmäki P; Moo-Young AJ Acta Obstet Gynecol Scand; 2003 Feb; 82(2):167-72. PubMed ID: 12648180 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]